Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 139-142

  Mamatha, Sopanahalli N ^a   Nagaraja, Dindagur ^a   Philip, Mariamma ^a   Christopher, Rita ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Asymmetric dimethylarginine; Early onset stroke; Risk marker

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PHTHALALDEHYDE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DERIVATIZATION; DIABETES MELLITUS; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME MECHANISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INDIAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARGININE; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; INDIA; LINEAR MODELS; MALE; MIDDLE AGED; RISK; STROKE; TIME FACTORS; YOUNG ADULT;

EID: 78650515157     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.026     Document Type: Article

References (38)

1. Mehndiratta M.M., Agarwal P., Sen K., Sharma B. Stroke in young adults: a study from a university hospital in north India. Med Sci Monit 2004, 10:535-541.
2. Lipska K., Sylaja P.N., Sarma P.S., et al. Risk factors for acute ischaemic stroke in young adult in south India. J Neurol Neurosurg Psychiatry 2007, 78:959-963.
3. Giannotti G., Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007, 32:568-572.
4. Vallance P. Chan N Endothelial function and nitric oxide: clinical relevance. Heart 2001, 85:342-350.
5. Strijdom H., Chamane N., Lochner A. Nitric oxide in the cardiovascular system: a simple molecule with complex actions. Cardiovasc J Afr 2009, 20:303-310.
6. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
7. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
8. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010, 47:17-28.
9. Teerlink T. ADMA metabolism and clearance. Vasc Med 2005, 10:S73-S81.
10. James M.L., Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006, 62:33-38.
11. Böger R.H., Bode-Böger S.M. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway and cardiovascular diseases. Semin Thromb Hemost 2000, 26:539-545.
12. Miyazaki H., Matzuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999, 99:1141-1146.
13. Iribarren C., Husson G., Sydow K., Wang B.Y., Sidney S., Cooke J.P. Asymmetric dimethylarginine and coronary artery calcification in young adults entering middle age: the CARDIA study. Eur J Cardiovasc Prev Rehabil 2007, 14:222-229.
14. Valkonen V.P., Paiva H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358:2127-2128.
15. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 2004, 109:1813-1818.
16. Schulze F., Carter A.M., Schwedhelm E., et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010, 208:518-523.
17. Khan U., Ahamad H., Patrick V., Markus H.S. Asymmetric dimethyl arginine in cerebral small vessel disease. Stroke 2007, 38:411-413.
18. Boger R.H., Bode B.S.M., Thiele W., Junker W., Alexander K., Frölich J.C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997, 95:2068-2074.
19. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002, 106:3143-21.
20. Melnyk S., Marta P., Igor P., Jean H.R., Jill J.S. A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. J Nutr Biochem 1999, 10:490-497.
21. Teerlink T., Robert J.N., Sigrid D.J., Van-Leeuwen P.A.M., et al. Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high performance liquid chromatography. Anal Biochem 2002, 303:131-137.
22. Yoo J.H., Lee S.C. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001, 158:425-430.
23. Nishiyama Y., Ueda M., Ken I.K., et al. Asymmetric dimethylarginine(ADMA) as a possible risk marker for ischemic stroke. J Neuro Sci 2010, 290:12-15.
24. Bode-Boger S.M., Muke J., Surdacki A., et al. Oral l-arginine improves endothelial function in healthy individuals older than 70years. Vasc Med 2003, 8:77-81.
25. McCarty M.F. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med Hypotheses 2004, 63:699-708.
26. Pikula A., Böger R.H., Beiser A.S., et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009, 40:2959-2964.
27. Leong T., Zylberstein D., Graham I., et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008, 28:961-967.
28. Wilson A., Shin D., Weatherby C., et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med 2010, 15:267-274.
29. Wang S., Jiang J.L., Hu C.P., Zhang X.J., Yang D.L., Li Y.J. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells. Diab Metab Res Rev 2007, 23:157-164.
30. Lielstein J.T., Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?. Am J Kidney Dis 2005, 46:186-202.
31. Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia. Vasc Med 2005, 10:S27-S33.
32. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996, 98:5-7.
33. Zakrzewicz D., Eickelberg O. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung disease. BMC Pulm Med 2009, 9-5.
34. Boger B.H. Asymmetric dimethylarginine(ADMA) modulates endothelial function-therapeutic implications. Vasc Med 2003, 8:141-151.
35. Boger R.H., Bode-boger S.M. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway and cardiovascular diseases. Semin Thromb Hemost 2000, 26:539-545.
36. Szolnoki Z. Reduced noncovalent connections in leukoaraiosis. Expert Rev Neurother 2008, 8:205-213.
37. Szolnoki Z. A dynamically changing intracellular water network serves as a universal regulator of the cell: the water-governed cycle. Biochem Biophys Res Commun 2007, 357:331-334.
38. Szolnoki Z. Chemical events behind leukoaraiosis: medicinal chemistry offers new insight into a specific microcirculation disturbance in the brain (a chemical approach to a frequent cerebral phenotype). Curr Med Chem 2007, 14:1027-1036.